Adnan İNCEBIYIK, Hacer UYANIKOĞLU, Sibel SAK, Ahmet B TURP, Güler ÇAKMAK, Neşe G HİLALİ

Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta

Background: Placenta percreta is the morbidly adherentform of all the placental invasion abnormalities. Thepathology that underlies placenta percreta is poorlyunderstood.Aims: To compare the levels of circulating vascularendothelial growth factor, placental growth factor andsoluble fms-like tyrosine kinase 1 in pregnant womenwith placenta percreta to a control group.Study Design: Case-control study.Methods: Twenty-two women who underwentcaesarean section due to placenta percreta and 22 womenwho underwent caesarean section for other obstetricreasons were included in this study. The diagnosis ofplacenta percreta was defined as extreme trophoblasticinvasion involving serosa of the uterus. Venous bloodsamples were collected for biochemical comparison ofcirculating vascular endothelial growth factor, placentalgrowth factor and soluble fms-like tyrosine kinase 1from all pregnant women.Results: Women with placenta percreta weresignificantly older, had higher gravidity, received morefrequent antenatal steroids and blood transfusions anddelivered at an earlier gestational age when comparedto the control group. In women with placenta percreta,preoperative circulating levels of vascular endothelialgrowth factor, placental growth factor and soluble fmsliketyrosine kinase 1 were lower than the controls(p

PDF

___

Wehrum MJ, Buhimschi IA, Salafia C, Thung S, Bahtiyar MO, Werner EF, et al. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast. Am J Obstet Gynecol 2011;204:411.e1-411.e11.
Hull AD, Moore TR. Multiple repeat cesareans and the threat of placenta accreta: incidence, diagnosis, management. Clin Perinatol 2011;38:285- 96.
Demir R, Kaufmann P, Castellucci M, Erbengi T, Kotowski A. Fetal vasculogenesis and angiogenesis in human placental villi. Acta Anat (Basel) 1989;136:190-203.
Dimitriadis E, Nie G, Hannan NJ, Paiva P, Salamonsen LA. Local regulation of implantation at the human fetal-maternal interface. Int J Dev Biol 2010;54:313-22.
Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
Ahmed A, Dunk C, Ahmad S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review. Placenta 2000;21(Suppl A):16-24.
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58.
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
Boufettal H, Feige JJ, Benharouga M, Aboussaouira T, Nadifi S, Mahdaoui S, et al. [Potential role of the angiogenic factor "EG-VEGF" in gestational trophoblastic diseases]. Pathol Biol (Paris) 2013;61:178-83.
Semczuk-Sikora A, Krzyzanowski A, Stachowicz N, Robak J, Kraczkowski J, Kwiatek M, et al. [Maternal serum concentration of angiogenic factors: PIGF, VEGF and VEGFR-1 and placental volume in pregnancies complicated by intrauterine growth restriction]. Ginekol Pol 2007;78:783-6.
Helske S, Vuorela P, Carpén O, Hornig C, Weich H, Halmesmäki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2001;7:205-10.
Biberoglu E, Kirbas A, Daglar K, Biberoglu K, Timur H, Demirtas C, et al. Serum angiogenic profile in abnormal placentation. J Matern Fetal Neonatal Med 2016;29:3193-7.
Pilloni E, Alemanno MG, Gaglioti P, Sciarrone A, Garofalo A, Biolcati M, et al. Accuracy of ultrasound in antenatal diagnosis of placental attachment disorders. Ultrasound Obstet Gynecol 2016;47:302-7.
Li CM, Hou L, Zhang H, Zhang WY. CCL17 Induces Trophoblast Migration and Invasion by Regulating Matrix Metalloproteinase and Integrin Expression in Human First-Trimester Placenta. Reprod Sci 2014.
Chaiworapongsa T, Romero R, Whitten AE, Korzeniewski SJ, Chaemsaithong P, Hernandez-Andrade E, et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med 2016;29:1214-28.
Borbely AU, Sandri S, Fernandes IR, Prado KM, Cardoso EC, Correa-Silva S, et al. The term basal plate of the human placenta as a source of functional extravillous trophoblast cells. Reprod Biol Endocrinol 2014;12:7.
Tseng JJ, Chou MM, Hsieh YT, Wen MC, Ho ES, Hsu SL. Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. Placenta 2006;27:70-8.
Charnock-Jones DS. Soluble flt-1 and the angiopoietins in the development and regulation of placental vasculature. J Anat 2002;200:607-15.
McMahon K, Karumanchi SA, Stillman IE, Cummings P, Patton D, Easterling T. Does soluble fms-like tyrosine kinase-1 regulate placental invasion? Insight from the invasive placenta. Am J Obstet Gynecol 2014;210:68.e1-4.